Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New bladder cancer cocktail aims to spare patients from bladder removal

NCT ID NCT05644041

First seen Mar 17, 2026 · Last updated May 21, 2026 · Updated 11 times

Summary

This study tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder for people with non-muscle invasive bladder cancer. It includes patients who have not had prior BCG therapy or whose BCG treatment failed. The goal is to see if this drug combo can eliminate or delay cancer recurrence, potentially offering an alternative to bladder removal surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for URINARY BLADDER CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Arizona Cancer Center

    RECRUITING

    Tucson, Arizona, 85721, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.